Sandbox/Alejandro: Difference between revisions
< Sandbox
No edit summary |
No edit summary |
||
Line 96: | Line 96: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cephalexin]] 25 mg/kg/day PO divided q6h x 5-10 days'''''<br> OR <br> ▸ '''''[[Dicloxacillin)]] 25 mg/kg/day PO divided q6h x 5-10 days'''''<br> OR <br>▸ '''''[[Clindamycin]] 10-13 mg/kg IV q6-8h (max:40 mg/kg/day)'''''<br> OR <br> ▸ '''''[[TMP-SMX]] 4-6 mg/kg PO q12h (TMP component)'''''<br> OR <br> ▸'''''[[Doxycycline]] | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cephalexin]] 25 mg/kg/day PO divided q6h x 5-10 days'''''<br> OR <br> ▸ '''''[[Dicloxacillin)]] 25 mg/kg/day PO divided q6h x 5-10 days'''''<br> OR <br>▸ '''''[[Clindamycin]] 10-13 mg/kg IV q6-8h (max:40 mg/kg/day)'''''<br> OR <br> ▸ '''''[[TMP-SMX]] 4-6 mg/kg PO q12h (TMP component)'''''<br> OR <br> ▸'''''[[Doxycycline]]¶ 2 mg/kg PO q12h† '''''<br> OR <br> ▸ '''''[[Linezolid]] 10 mg/kg PO q8h (max: 600mg/dose)''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL> <sup> | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL><sup>¶</sup> Not recommended for children < 8 years of age <br><sup>†</sup> For children ≤45 kg. Children >45 kg receive adult dosing. </SMALL> | ||
|- | |- | ||
|} | |} | ||
Line 120: | Line 120: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Linezolid]] 10 mg/kg PO q8h (max: 600mg/dose)'''''<br> OR <br> ▸ '''''[[Clindamycin]] 10-13 mg/kg IV q6-8h (max:40 mg/kg/day)'''''<BR> OR <BR> ▸ '''''[[Minocycline]] 4 mg/kg PO 1 dose, then2 mg/kg/dose PO q12h '''''<BR> OR <BR> ▸ '''''[[Doxycycline]] | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Linezolid]] 10 mg/kg PO q8h (max: 600mg/dose)'''''<br> OR <br> ▸ '''''[[Clindamycin]] 10-13 mg/kg IV q6-8h (max:40 mg/kg/day)'''''<BR> OR <BR> ▸ '''''[[Minocycline]] 4 mg/kg PO 1 dose, then2 mg/kg/dose PO q12h '''''<BR> OR <BR> ▸ '''''[[Doxycycline]]¶ 2 mg/kg PO q12h†'''''<BR> OR <BR> ▸ '''''[[TMP-SMX]] 4-6 mg/kg PO q12h (TMP component)''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL> <sup> | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL><sup>¶</sup> Not recommended for children < 8 years of age <br><sup>†</sup> For children ≤45 kg. Children >45 kg receive adult dosing. </SMALL> | ||
|- | |- | ||
|} | |} |
Revision as of 20:54, 23 May 2014
Empiric TherapyAdapted from Clinical Practice Guidelines CID 2011[1] and Guidelines for Skin and Soft-Tissue Infections CID 2005[2]
▸ Click on the following categories to expand treatment regimens.
Cellulitis Non-Purulent Cellulitis ▸ Adults ▸ Children age >28 days Purulent Cellulitis ▸ Adults ▸ Children age >28 days Complicated Cellulitis† ▸ Adults ▸ Children age >28 days
|
|
Note:
- Treatment of cellulitis in neonates usually requires hospitalization and parenteral therapy. Oral therapy is given for completion of the treatment when the patogen is unknown.
- Optimal dose should be based on determination of serum concentrations.
- The above antibiotic regimen is NOT for initial empirical treatment of infections involving the face.
- Dose alteration for renal insufficiency may be needed in case of cephalosporins.
- Clindamycin is an alternate therapy for patients at risk of severe hypersensitivity reaction to penicillins and cephalosporins.
- Doxycycline is NOT recommended for children <8 years of age.
- Studies have shown an increase in treatment failure with TMP-SMX compared to other agents for cellulitis in children, reflecting TMP-SMX less action against Group A streptococcus.[3]
References
- ↑ Mathews, CJ.; Weston, VC.; Jones, A.; Field, M.; Coakley, G. (2010). "Bacterial septic arthritis in adults". Lancet. 375 (9717): 846–55. doi:10.1016/S0140-6736(09)61595-6. PMID 20206778. Unknown parameter
|month=
ignored (help) - ↑ Dennis L. Stevens, Alan L. Bisno, Henry F. Chambers, E. Dale Everett, Patchen Dellinger, Ellie J. C. Goldstein, Sherwood L. Gorbach, Jan V. Hirschmann, Edward L. Kaplan, Jose G. Montoya & James C. Wade (2005). "Practice guidelines for the diagnosis and management of skin and soft-tissue infections". Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 41 (10): 1373–1406. doi:10.1086/497143. PMID 16231249. Unknown parameter
|month=
ignored (help) - ↑ Elliott DJ, Zaoutis TE, Troxel AB, Loh A, Keren R (2009). "Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus". Pediatrics. 123 (6): e959–66. doi:10.1542/peds.2008-2428. PMID 19470525.